New Targets,
New Therapeutics

Date 19 TH.
JUN.

From 1 PM To 9 PM EST

Westin Waltham, Annual Dinner Conference Center, 70 3rd Ave, Waltham, MA 02451
The Biocytogen Symposium 2025 is poised to be a premier forum for scientific exchange, bringing together leading experts from industry and academia to explore the forefront of therapeutic innovation. With a focus on the discovery of new drug targets and novel drug development strategies, this symposium will foster insightful scientific exchange and collaboration. Attendees will gain exclusive access to cutting-edge research, transformative methodologies, and emerging trends shaping the future of drug discovery and development.
Speaker & Panelist

Yanfei Linda Ma, Ph.D.

Vice President, Research-Immunology

Eli Lilly and Company

Saso Cemerski, Ph.D.

Executive Director, Head of Immune Engagers

AstraZeneca

Ben Deverman, Ph.D.

Institute scientist & Sr. Director, Vector Engineering

Broad Institute of MIT and Harvard

Wade Blair, Ph.D.

Chief Scientific Officer

IntegerBio

Karsten Sauer, Ph.D.

Vice President, Pre‑Clinical R&D

Cullinan Therapeutics, Inc.

Yi (Benny) Yang, Ph.D.

Chief Scientific Officer

Biocytogen

Yuelei Shen, Ph.D.

President & CEO

Biocytogen

Agenda

Thursday June 19 | 1-9 PM EST

  • 1:00-1:30

    Registration and Welcome

  • 1:30-1:45

    Opening Remarks
    Yuelei Shen, Ph.D.President & CEOBiocytogen

  • 1:45-2:10

    Speaker Session 1
    Yanfei Linda Ma, Ph.D.Vice President, Research-ImmunologyEli Lilly and Company
    Topic: Pharmacological Evaluation of a Pegylated Urocortin -1 Peptide in Experimental Autoimmune Disease Model

  • 2:10-2:35

    Speaker Session 2
    Ben Deverman, Ph.D.Institute scientist & Sr. Director, Vector EngineeringBroad Institute of MIT and Harvard
    Topic: Humanized TFR1 Mice: Applications from Discovery to Validation to Preclinical Toxicology Studies

  • 2:35-3:00

    Coffee Break

  • 3:00-3:25

    Speaker Session 3
    Saso Cemerski, Ph.D.Executive Director, Head of Immune EngagersAstraZeneca
    Topic: Development of Novel, CD8-guided, T Cell Engagers for the Treatment of Solid Tumors and Hematological Malignancies

  • 3:25-3:50

    Speaker Session 4
    Karsten Sauer, Ph.D.Vice President, Pre‑Clinical R&DCullinan Therapeutics, Inc.
    Topic: Preclinical Development of CLN-978, a Clinical CD3 x CD19 T Cell Engager

  • 3:50-4:15

    Speaker Session 5
    Yi Yang, Ph.D.Chief Scientific OfficerBiocytogen
    Topic: Minecrafting the Future: Designing Novel Multispecific ADCs via RenBiologics’ Fully Human Antibody Platform

  • 4:15-5:15

    Panel Discussion
    Yi Yang, Ph.D.Chief Scientific OfficerBiocytogen
    Yanfei Linda Ma, Ph.D.Vice President, ImmunologyEli Lilly and Company
    Wade Blair, Ph.D.Chief Scientific OfficerIntegerBio

  • 5:15-5:40

    Transition to Biocytogen Facility

  • 5:40-9:00

    Dinner Reception & Networking & Happy Hour